Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

15. März 2022 08:32 ET | Quelle: Allarity Therapeutics, Inc.

Allarity Therapeutics Provides Update on Dovitinib Program

FOR IMMEDIATE RELEASE Allarity has requested a Type C meeting with the FDA to discuss potential clinical paths to support approval of dovitinib in view of the regulatory agency’s recent Refusal to...
29. April 2021 10:31 ET | Quelle: Allarity Therapeutics A/S

Allarity Therapeutics To Present a Dovitinib-DRP® e-Poster at the European Association for Cancer Research (EACR) 2021 Virtual Congress

- Poster title: A novel drug response predictor (DRP®) mRNA biomarker for the multi tyrosine kinase inhibitor dovitinib - Poster provides new details of the DRP® companion diagnostic for dovitinib,...
09. März 2021 07:00 ET | Quelle: Allarity Therapeutics A/S

Allarity Therapeutics Announces Positive Data from Preclinical Study of Dovitinib in Osteosarcoma

- Treatment of animal osteosarcoma models with dovitinib increased the median survival time by 50 % as compared to control animals. Press release Hørsholm, Denmark (9 March 2021) – Allarity...
23. Oktober 2020 02:35 ET | Quelle: Allarity Therapeutics A/S

Allarity Therapeutics Provides Update on Dovitinib Program

Press release Hørsholm, Denmark (23 October 2020) – Allarity Therapeutics A/S (“Allarity” or the “Company”) today announced several updates related to its planned filing of a new drug...